Axonics Inc. (AXNX) - Debt to Equity

The Axonics, Inc. (AXNX) price chart illustrates the dynamics of the individual debt-to-equity ratio, which stands at 0.33. Axonics, Inc. (AXNX) develops urinary regulation implants, where long-lasting batteries ensure lifelong user dependence on ancillary services. The $3.7 billion acquisition by the Boston Scientific behemoth confirmed the high value of its assets, while its independence from global crises makes this defensive business resilient to macroeconomic fluctuations.

This indicator determines the degree of business dependence on borrowed funds by comparing total liabilities to equity to assess financial stability and bankruptcy risks. By analyzing the ratio of total liabilities to equity, an investor can see how the high margins of Axonics, Inc. (AXNX) urological implants and the upcoming integration into the Boston Scientific network allow for the optimization of the debt load.